5mg | Tablets
From September 1st 2021 onwards, Xigduo® 5 mg for the treatment of adults with type 2 diabetes mellitus with a very high risk of cardiovascular disease is fully reimbursed by the health insurer.
With this reimbursement, the Reimbursement Solution TerugBetaalRegeling (TBR) of Xigduo® 5 mg for patients with diabetes and a very high risk of cardiovascular disease will expire on 1 September 2021. For patients who do NOT fall under these new reimbursement conditions, a decision will be made in 6 months on the continuation and implementation of the current TBR and the current TBR will continue to apply.
Very high risk means:
• previously proven cardiovascular disease; and/or
• chronic kidney damage with
− eGFR 30-59 ml/min per 1.73m2 with moderately elevated albuminuria (ACR > 3 mg/mmol/l); or
− eGFR ≥ 60 ml/min per 1.73 m2 with severely elevated albuminuria (ACR>30 mg/mmol)
For a complete reimbursment overview of Forxiga® (dapagliflozine) 10 mg/Xigduo 5 mg, click here.
|Dose||Xigduo® 5mg and Forxiga® 10mg|
|Active ingredient||DAPAGLIFLOZINE WITH METFORMINE and DAPAGLIFLOZINE|
Declarations of Xigduo® 5 mg for patients with diabetes and a very high risk of cardiovascular disease, with an issue date between July 1st 2019 and September 1st 2021, can still be submitted to TBR Nederland until December 31, 2021. Prescriptions from the 1st of September will be fully reimbursed by the health insurer.
You can only submit invoices for patients with diabetes and a very high risk of cardiovascular disease, with an issue date between July 1st 2019 and September 1st 2021. Invoices with an issue date between those dates can still be submitted to TBR Nederland until December 31, 2021.
Patients and pharamcists can claim online and will receive the reimbursement within 5 working days.
Patients can claim by post and will receive their reimbursement within 15 working days.
Please mail the Claim Form and attachments to:
1180 LA Amstelveen
Quickly check the maximum contribution you have to pay for your medicine